Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer

BACKGROUND: Iniparib (BSI-201), a novel anticancer agent thought to have poly(ADP-ribose) polymerase (PARP) inhibitory activity and synergy with both gemcitabine and carboplatin (GC) was evaluated in 2 cohorts with GC. METHODS: Parallel multicenter, single-arm, phase II studies using a Simon two-sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Penson, Richard T, Ambrosio, Allison J, Whalen, Christin A, Krasner, Carolyn N, Konstantinopoulos, Panagiotis A, Bradley, Charles, Matulonis, Ursula A, Birrer, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Gynecologic Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020803/
https://www.ncbi.nlm.nih.gov/pubmed/36718018
http://dx.doi.org/10.1093/oncolo/oyac275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020803/
https://www.ncbi.nlm.nih.gov/pubmed/36718018
http://dx.doi.org/10.1093/oncolo/oyac275

Ejemplares similares